NVCR: SEC Form S-8 filed by NovoCure Limited
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NVCR
Across the 22 sessions after earlier NVCR headlines, the stock closed higher 9 times and lower 13 times, with a median move of 4.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NVCR | SPY |
|---|---|---|---|
| Oct 29, 2026 | Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance | -7.5% | -0.4% |
| Oct 28, 2026 | Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement | -3.1% | +0.3% |
| Oct 1, 2026 | Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancerand 1 other headline that session | -0.2% | +0.2% |
| Sep 2, 2026 | Novocure Announces Upcoming Investor Events | +2.6% | +0.4% |
| Jul 23, 2026 | Novocure Reports Second Quarter 2026 Financial Results | +28.4% | -1.2% |
| Jul 13, 2026 | Analyst resumed coverage on NovoCure with a new price target | -1.3% | -0.8% |
Quantisnow market dataNASDAQ
NVCR
NovoCure Limited
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2015
Get push alerts for NVCR
Full NVCR profile on Quantisnow Follow NVCR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time